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1. Introduction 
 
Even in this age of medicine, acute liver disease is still primarily treated in the 
same way as a decade ago; through the use of a liver transplant. However, due to the 
increase in liver disease and the persistent shortage of donor organs, the development of a 
bioartificial liver (BAL) has been the center of many research projects around the world. 
Even so, in the last two decades, there has only been little advancement on the 
development of a suitable human liver representative bioreactor. Although tissue-
engineering methods have improved, a bioreactor still needs to be developed that can 
emulate the liver in order to properly develop and test hepatocytes to be used in a 
bioartificial liver. This BAL model must be able to first of all maintain cell viability, as 
well as mimic gas exchange and nutrient delivery. However, the development of a 
suitable BAL is prolonged due to the financial aspect of pharmacology testing. The cost 
of testing a single pharmaceutical compound on hepatocytes in vivo can exceed millions 
of dollars in order to satisfy government regulations. The fact is that there are many new 
compounds that are synthesized each year that could fight liver disease, but the cost of in 
vivo testing is far too high [8]. By creating a BAL to model the in vivo pathways and 
mechanisms in the liver, an understanding of integration and the effects of consequent 
pharmaceutical compounds can be expedited and testing can be made more affordable. 
 
2. Background 
 
2.1 Acute Liver Failure and Methods of Treatment 
According to the American Liver Foundation, over 45,000 people die of liver 
disease/failure annually [12]. Generally, liver disease is caused from the buildup of fats, 
sugars, and other metabolites due to some other underlying problem [2]. These buildups 
cause cirrhosis, which is a degenerative process in the liver that causes the destruction of 
hepatocytes (liver cells) and the eventual contraction of the organ [6]. Liver failure causes 
the disruption of the body’s acid-base balance, metabolic instability, disruption of energy 
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supply, among others. Unfortunately, the mortality rate of acute liver failure is 80-90%, 
with death within a week or two. Even though technology today has improved in terms of 
success of treatment after transplantation, the rapid progression of the disease often 
makes this procedure unviable due to human organ shortages worldwide. To fill this 
deficiency, there are several alternative methods of treatment under exploration including 
tissue engineering implantable constructs, transgenic xenotransplantation, and 
extracorporeal bioartificial liver devices [1]. Although each method has its advantages 
and disadvantages, none have had consistent and absolute success in providing acute care 
to patients with liver failure. BALs have been researched for many decades, with a great 
deal of progress to show; however, even the commercially available products that claim 
to functionally mimic a liver are not without their flaws.  
 
2.2 Hepatic Acinus 
The hepatic acinus is the smallest functional unit of the liver [7]. To create an 
effective bioreactor, this unit of the liver must be modeled. In general, a liver lobule 
refers to the tissue that is centered on a single central vein, a branch of the hepatic artery. 
The hepatic acinus, however, is more along a branch of a portal triad and shows how well 
the hepatocytes in the area are oxygenated, along with the oxygen gradient. This unit is 
important as it shows us that the hepatocytes that are slightly closer to the central vein are 
less oxygenated than those right along the edge of the liver lobule.  
 
2.3 Previous Prominent Bioreactor Designs 
These extracorporeal devices utilize isolated hepatocytes in a chamber that allows 
the cells to survive and continue to provide functional support, similar to that in vivo. In 
order to create a bioreactor to emulate the hepatic function for pharmaceutical testing, it 
is important to see where previous designs have failed, as well as succeeded. Three 
prominent designs have emerged in the past 50 years of extracorporeal BAL history. 
Table 1 outlines these three approaches and highlights the advantages and disadvantages 
of each. 
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Table 1. Prominent types of bioreactors [9] 
 
2.3.1 HepaAssist 2000 
Circe Biomedical has a BAL System [4], termed the HepaAssist 2000, which is in 
its early stages of clinical trials. This liver support system takes a compartmental 
approach, along with the use of hollow fibers. To use this device for treatment, the 
plasma goes into a charcoal column, where it is pumped through two charcoal filters. 
These filters act as Kuppfer cells and filter the plasma from particulates and bacteria that 
might be harmful to the hepatocytes in the next compartment. After this basic filtration, 
the plasma enters the actual bioreactor, which contains a porcine-hepatocyte lined hollow 
fiber column. This membrane is porous with a pore size of 0.2µm, small enough to 
prevent the passage of whole hepatocytes cells, but large enough to allow protein bound 
toxins to travel between the plasma and hepatocyte chamber. After the plasma is run 
through this chamber, it is returned with the blood separated earlier and sent back to the 
body. Although this design shows results when used for a 6-hour treatment, the problem 
is that in order for pharmaceutical testing, 6 hours is not long enough to evaluate if the 
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results are significant. Hepatocytes in the hollow fiber chamber died out after 8-9 hours 
of experimentation.  
 
2.3.2 Modular Extracorporeal Liver System 
Dr. Gerlach’s Modular Extracorporeal Liver System (MELS) consists of a 4-
chamber design [10]. The four chambers include the cellular compartment and pathway 
compartments for nutrients, gas, and waste. The device relies on a network of thin hollow 
fiber membranes, in which hepatocytes are kept alive through the nutrients and gas 
pumped in. Inside the bioreactor, each of the functional units consists of a flow pathway 
formed by two plates. The upper plate consists of an array of gas filled hollow fibers, and 
the bottom plate is where the hepatocytes are attached. The separated blood plasma then 
flows through the channel formed and comes in direct contact with the hepatocytes. The 
flow through this device, depending on the number of channels available can reach 
100ml/min, which is quite high, and the cells supposedly can survive up to one month. 
The problem with this bioreactor is that its media/biomass ratio is too high to mimic liver 
function for pharmaceutical testing. 
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2.3.3 Multi-coaxial BAL 
ADMET Technologies has been working on a multi-coaxial bioreactor to serve as 
a human bioartificial liver [7]. This bioreactor attempts to mimic the liver lobule/acinus 
in both structure and dimension, which had not been done before. The reason for its 
success is that the hollow fiber within hollow fiber design allows for precise control of 
the diffusion distances of nutrients to cells. In the case of testing pharmaceutical 
compounds, this is particularly important. Dr. Macdonald, a professor at UNC, was 
working on a modified version of this bioreactor with a gas chamber on the outside layer 
on which he did extensive testing which showed signs that this bioreactor was able to 
mimic liver function, as well as keep the hepatocytes alive for long periods of time, even 
up to 30 days. This bioreactor had a slightly larger media-biomass ratio than needed, due 
to the available hollow fiber membranes at the time. Hollow fibers are one of the more 
practical approaches to allow for the exchange of small molecules from one chamber to 
another.  
 
3. New Bioreactor Design  
 
3.1 Goals and Task 
The Hamner Institute for Health Sciences in RTP, North Carolina is interested in 
Physiological Based Pharmacokinetic Modeling (PBPK) for various drugs and chemicals 
through the liver. PBPK is a modeling method to predict mathematically the distribution, 
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metabolism, and excretion of substances in the human body [3]. This technique is the 
prominent method in order to assess the risks and effects of a drug in the pharmaceutical 
research field. Even in five decades of extracorporeal bioarticial liver devices, there is 
still a need for a device to model human pharmacokinetics in the liver. 
Based on the previous bioreactors out there, some goals can be set for an ideal 
bioreactor for the task at hand. First of all, for PBPK, the blood (media) to tissue 
(biomass) ratio needs to be optimized close to 1.34:1 [6], to accurately mimic the liver 
acinus. This is important as to not overwhelm the hepatocytes with a volume of blood 
that they cannot handle [6]. Looking at the previous designs, with the exception of the 
multicoaxial bioreactor, the blood-biomass ratio was too high. This high ratio could be 
the reason that the previous designs were not able to keep the hepatocytes alive for a long 
duration of time. Further, the oxygen gradient also needs to be properly optimized. When 
looking at the liver acinus, the central vein (deoxygenated) runs along the middle of a 
lobule, and the portal triad runs on the outside of the lobule. Then, as the blood travels 
through the acinus, it travels from the oxygenated vessel, through hepatocytes, to the 
deoxygenated vein. In a bioreactor, it becomes difficult to mimic this gradient. In the 
multicoaxial bioreactor design, the gas chamber is only on the outside of the media fiber, 
which removes any chance of an oxygen gradient. Also, for testing with pharmaceutical 
compounds, the scientists must have access to the cells to be able to run imaging and 
other tests. When looking at Circe’s bioreactor model, the porcine hepatocytes are sealed 
inside the internal hollow fiber. If these cells were removed, the bioreactor would be 
rendered useless. Therefore, in order to provide access to the cells without destroying the 
function of the bioreactor, the bioreactor must be easily disassembled. Ease of inoculation 
should also be taken into consideration. Additional factors to consider for PBPK include 
accommodating for both alginate encapsulates and cell aggregates (spheroids), along with 
taking into account the material binding factors of Albumin and Alpha-1-glygoprotein 
(AAG). Albumin and AAG are both markers used in PBPK to gauge a quantitative 
understanding of drug action and distribution [5]. Last, for the experiments run for PBPK, 
long-term function is also a factor as these experiments can be run for up to 60 days. For 
P a g e  | 9 
 
practicality’s sake, the cost of the device must be reasonable for an honors thesis project, 
as opposed to Gerlach’s device that costs $3000. From previous bioreactor designs, it 
seems that the use of hollow fibers seems to be the best way to house the hepatocytes. 
However, after some initial research on the availability of hollow fibers in the market 
today, an alternate solution is required. Hollow fibers are rarely sold independently today; 
they are only available as part of a pre-existing bioreactor. This option would be far too 
expensive. The question then arises as to how to build upon the success of the multi-
coaxial bioreactor, but without the use of hollow fibers. 
 
3.2 Design 
The new design is based on an unraveled multi-coaxial bioreactor. However, 
instead of using hollow fibers, flat membranes are used. These membranes come in a 
variety of pore sizes, and are easily available from multiple manufacturers at a very 
reasonable cost. The new design can be described as a flat [2] packed bed bioreactor with 
three compartments, separated by the PES membranes.  
 
 
 
 
The middle compartment is where the cell culture will be housed, whereas the two 
outside compartments will where the media flow will pass through. The size and shape of 
the individual compartments is what is most important. In order to assure that the media 
will come into contact with the cells, the cross-sectional area of the media compartment 
is larger than the cell compartment. As far as the shape of the compartments is concerned, 
it can be described as a teardrop shape.  
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To determine the effectiveness of the teardrop based shape of the media compartments, 
fluid dynamics were analyzed using COMSOL Multiphysics, with an input velocity of 
1mL/min. 
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This shape ideally allows for a flow that minimizes 
dead flow areas and promotes uniform residence 
time within all portions of the compartment. 
However, after some initial analysis, it can be seen 
that there are pressure peaks near the two inlet and 
outlet ports, as well as nonuniform flow velocity 
down the center of the chamber. These issues must 
be addressed in order to maintain a uniform flow 
and pressure within the cell chamber. To 
address the issue of the high pressure points, 
the cell compartment is scaled down so that 
the cells themselves do not undergo a strong shear stress. As shown to the right, the cell 
compartment will maintain the teardrop-based shape, without coming into direct contact 
with the pressure points. When making this design change, it is important to keep in mind 
the blood to biomass ratio; to keep the ratio as close to 1.34:1, the cell compartment size 
must be maximized, without hindering on the pressure points. Further, the nonuniform 
flow distribution can be addressed using a tapered media compartment. Be gradually 
decreasing the depth of the compartment from the narrow end to the wide end, the flow 
can be better distributed. Due to the nature of laminar flow fluid dynamics in the 
compartment, it is difficult to gain even flow near the edges of the compartment; 
however, as long as there is a uniform flow within the cell compartment area, it is not of 
concern. At the narrow end of the compartment, a larger depth 
 
When looking at the maximum diffusion distance, there are two factors that must 
be balanced: maximum known diffusion distance for hepatocytes, and achieving a proper 
blood to biomass ratio. From past experiments, the maximum diffusion distance depends 
on how the hepatocytes are encapsulated [13]. It was found that if encapsulated in 
spheroids with a diameter of 500µm, a maximum cell compartment width of 2mm can be 
achieved. On the other hand, the minimum width required is based on structural integrity 
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limitations. Initially, the cell compartment width was set to 1.8mm; however based on 
final material choices and initial experimental data on hepatocyte function, this can be 
changed. In order to minimize the blood-tissue ratio for the proper metabolism ratios, the 
media compartment widths can be determined using the width of cell compartment. This 
is the area that the aforementioned bioreactors lack the most. Therefore, for initial testing, 
the media compartment was designed to be 2mm in width as well. Including both media 
compartments on either side of the cell compartment, this allows for a blood-tissue ratio 
of roughly 1.97:1. This ratio is far more representative of the blood-biomass ratio in the 
liver acinus than any other prominent BALs. 
 
Due to the nature of the flat packed bed bioreactor, there are also multiple flow 
configurations that can be reached; Cross-Flow and Dead-Ended-Flow. Although this 
functionality adds new application possibilities, after examination of prominent research 
in the field, dead-ended flow eventually results in the clogging of the filter pores with 
albumin and other byproducts.  
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The ability to run experiments in different flow 
configurations is not vital, however, it allows for 
more flexibility in the types of experiments that can 
be run. The ability to pressurize one side of the 
bioreactor at a time also allows for better 
inoculation technique. By attaching a lab vacuum to 
both inlet and outlet of one media compartment 
while the other side lies open allows a vacuum-sealed inoculation; as the mixture of 
media and cells is placed into the cell chamber, the excess media is suctioned out through 
the PES filter. This method could be done without the use of a vacuum, but it would take 
considerably longer as the media would have to diffuse out on its own. Nonetheless, with 
this technique, the chamber was inoculated very evenly and fairly packed.  
 
Further on, this new design provides easy access to the cells to perform metabolic 
analysis. The snap-close and screw-seal mechanism can easily be detached, allowing for 
the three compartments to come apart. Unlike previous bioreactors, even after 
disassembly, the bioreactor is still functional. By just replacing the PES membranes, the 
bioreactor can be reset and used again. The main benefit of using a flatbed design is that 
flat membranes are relatively inexpensive to their hollow fiber counter parts. The 
membranes that were used initially had a 0.47µm pore size and cost roughly $1 each. 
Filters are usually where the bulk of the cost lies; by minimizing that cost, the remaining 
parts of the bioreactor are relatively affordable. 
 
3.3 Prototype 
Taking all factors above into consideration the following design was finalized. 
This design has a cell compartment volume of 1.39mL, and a media compartment volume 
of 1.37mL. Therefore, overall, the blood to biomass ratio for this flat bed packed 
bioreactor is 1.97:1. The cell compartment is positioned and sized just small enough to 
maximize distribution of flow and to avoid the pressure points.   
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With the final design completed, a sample prototype was printed using FDM and a high 
precision 3D printer.  
 
 
3.4 Manufacturing 
 The 3D printed material is not suitable for a final 
product due to drug binding and liquid permeability 
reasons. A chemically inert, rigid elastomer is needed for 
the final build material. After some examination of the 
materials available within a reasonable price range, 
polysulfone is chosen. Since the bioreactor is to be used 
in a PBPK modeling system, drug-material binding is a 
important factor to consider. Polysulfone is known to be 
chemically rigid, along with a low 0.3% water absorption 
rate. Another important consideration when choosing the 
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build material is its rigidity to manufacturing techniques. Polysulfone has a tensile 
strength of 10,200 psi and impact strength of 1.3 ft-lbs/in, which are both greater than 
most other elastomers that are chemically rigid. As far as the O-rings used to seal the 3 
chambers, EPDM (ethylene propylene diene monomer) rubber O-rings were used to 
provide a strong seal to water. The polysulfone was milled using a CNC mill, and a 
variety of mill and drill bits based on individual sizes and depths. Overall, the process 
took around 30 hours of milling. For future iterations of this bioreactor, the 
manufacturing time would be greatly decreased as now I have some experience with how 
to mill polysulfone, and take into account its material properties. Throughout the 
manufacturing process, I learned a great deal about different manufacturing processes and 
how to better design the bioreactor in the future to allow for easier manufacturing. 
Overall, the final product was near perfect, with very few inconsistencies from the 
Solidworks design to the final product.  
        
 
4. Initial Experimentation and Next Steps 
 
Initial experiments were run using inoculated alginate beads. The objective of this 
initial experiment was to gauge an understanding of if the bioreactor was capable of 
performing long-term tests and if the filter pore sizes were adequate for various flow 
configurations. The first aspect to test is the flow and if it is equalized throughout the 
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whole cell compartment; in other words, optimize the radial flow. To do so, first empty 
alginate encapsulates will be made and injected into the cell compartment. By varying the 
input and exit tubing, the linear flow rates can be modified. If the flow through one media 
compartment is held constant, and the exit flow of the second compartment is modulated, 
the effective radial flows can be analyzed by studying the encapsulated beads. After 
initially attempting this with alginate beads, it seemed that the radial flow was plenty, in 
the dead ended flow configuration (input flow at 1mL/min).   
Therefore, the chamber was then inoculated with 1:1 Alginate: Rat Hepatocytes. 
To this mix, trypan blue was added in a non-lethal dose (100 ppm) in order to increase 
visibility of the cells when inoculating. The oxygenation/perfusion tubing was setup in 
such a way that the incoming and outgoing media was oxygenated over the course of 20 
cm, with an aeration tube. This setup was allowed to run for 3 days with 2mM CaCl2 
DMEM based media. The CaCl2 was added in order to keep the alginate beads intact. 
 
Unfortunately, this initial experiment resulted in the clogging of the filter pores. 
In the dead ended flow configuration, there was too much albumin produced in the cell 
chamber, with very little time to diffuse out. However, this is not a major set back, as this 
just shows that in the dead-ended flow configuration, it is required that the filter pore size 
be much larger to accommodate for the induced radial flow. Initial results from the first 
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24 hours of the run show that the cells were alive and consuming glucose and producing 
lactate. Overall, the experiment still supports the success of the bioreactor.  
From the first experiment, I have gauged an understanding of what needs to be 
tested next. First, the pore size of the filter needs to be increased. This is a inexpensive 
change, and if needed, nitex flat sheet membranes can be used. For the next experiment, 
the cross-flow configuration will be used in order to maximize the concept of pressure 
induced radial flow. The data collection will involve testing for the following quantitative 
measurements: Glucose consumption, lactate production, enzyme leakage (Lactate 
Dehydrogenase, ALT and ASP rates. The cells will also be analyzed for its metabolic 
fluxome [11] as well as analyzed under a microscope for structural integrity and viability.  
 
5. Conclusion 
 The need for a pharmacokinetically compatible bioartificial liver was the primary 
motive for this project. After looking at all the methods of current treatment and solutions 
for acute liver disease, it becomes apparent that there are very few pharmaceutical based 
solutions available now. The only way to expedite this process is to allow scientists to 
have a way to test their drug without the expensive process of live testing. Obviously, to 
get the drug approved, it must go through clinical trials, but what if there was a precursor 
available that mimicked the body and liver in function. This, the serial organ system, will 
represent the human body in a functional ideology. After examining the various types of 
hollow fiber bioreactors available in the present and the past, it becomes apparent that the 
Multi-Coaxial bioreactor has the greatest promise. It has a low blood-biomass ratio, and 
has proved to be able to keep cells alive for long durations. However, since hollow fibers 
are no longer readily found, I took the design of the hollow fiber and modeled an 
unraveled form; the packed flat bed bioartificial liver. After modeling the fluid dynamics 
and doing extensive research on prior bioreactors, and where they have succeeded and 
failed, a design was formed. After some initial printed builds, it became apparent that the 
bioreactor needed some improvements, mainly in sealing better and minimizing the blood 
to biomass ratio. After some improved versions of the design, a second prototype was 
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finalized on, which had a blood to biomass ratio of 1.97:1, which is within reason. This 
prototype was then manufactured from polysulfone with the use of CNC technologies. 
After some initial tests at the Hamner Institute, the bioreactor shows great promise, and 
indications that it is capable of sustaining cell life. I plan to further research and test the 
bioreactor, as well as create an improved version based on my experiences post-
construction.  This process of designing a bioreactor was far more involved and critical 
than I imagined. However, I gained invaluable experience in the field of bioreactors and 
bioartificial systems.  
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